Immunocore Eye Cancer Cell Therapy Scores European Approval


The European Commission (EC) has approved Immunocore Holdings plc's IMCR Kimmtrak (tebentafusp) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). 

  • Kimmtrak is a novel bispecific protein comprised of a soluble T cell receptor that is fused to an anti-CD3 immune-effector function.
  • The EC approval follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in February 2022.
  • The CHMP recommendation of Kimmtrak is based on the results of Immunocore's Phase 3 IMCgp100-202 clinical trial.
  • Related: FDA Approves First T Cell Receptor Therapy From Immunocore For Eye Cancer.
  • Kimmtrak demonstrated a median overall survival benefit as a first-line treatment. 
  • The OS Hazard Ratio (HR) in the intent-to-treat population favored Kimmtrak, HR=0.51, over the investigator's choice of treatment (82% pembrolizumab; 13% ipilimumab; 6% dacarbazine). 
  • In this study IMCgp100-202, 43% of patients received treatment beyond progression with tebentafusp with no new safety signals identified. 
  • Price Action: IMCR shares are up 4.32% at $32.39 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsEuropean Medicines Agency
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!